These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1046 related articles for article (PubMed ID: 16048918)

  • 1. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
    Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
    Reyes N; Skinner R; Benton BM; Krause KM; Shelton J; Obedencio GP; Hegde SS
    J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
    Boucher HW; Thauvin-Eliopoulos C; Loebenberg D; Eliopoulos GM
    Antimicrob Agents Chemother; 2001 Jan; 45(1):208-11. PubMed ID: 11120967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY; Calhoun JH; Thomas TS; Wirtz ED
    J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW; Patron RL; Goldstein BP; Archer GL
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a mouse model of induced Staphylococcus aureus infective endocarditis.
    Gibson GW; Kreuser SC; Riley JM; Rosebury-Smith WS; Courtney CL; Juneau PL; Hollembaek JM; Zhu T; Huband MD; Brammer DW; Brieland JK; Sulavik MC
    Comp Med; 2007 Dec; 57(6):563-9. PubMed ID: 18246868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.